Exhibit 10.46
CO-EXCLUSIVE OEM SUPPLY
AGREEMENT
THIS CO-EXCLUSIVE OEM SUPPLY AGREEMENT (the
“Agreement”) is made as of this 7 th day of
June, 2009 (the “Effective Date”), by and between
Millipore Corporation having an office at 28820 Single Oak Drive,
Temecula, CA 92590 (“Millipore”) and
Embryome Sciences, Inc., a California corporation and subsidiary of
BioTime, Inc., with an address at 1301 Harbor Bay Parkway, Alameda,
CA 94502 (“ES”).
Recitals
WHEREAS, ES manufactures and sells certain
biological products used in biological research;
WHEREAS, ES
desires to transfer, manufacture and supply Millipore with certain
quantities of products for its use and resale under
Millipore’s own brand and labeling; and
NOW, THEREFORE, in consideration of the mutual
covenants set forth in this Agreement and for other good and
valuable consideration, the parties hereby agree as
follows:
1.1 “Affiliates”
means an entity which directly or indirectly controls, is
controlled by, or is under common control with a
party. The term “control” as used in the
preceding sentence means the possession of the power to direct or
call for the direction of the management and policies of an entity,
whether through ownership of a majority of the outstanding voting
securities, by contract or otherwise.
1.2 “Agreement”
means this Agreement, as it may be amended from time to time,
including the Schedules attached hereto.
1.3 “Product”
or “Products” shall mean those certain products, as set
forth in Exhibit A, as may be amended from time to time, to include
(a) any other products that ES and Millipore may from time to time
agree to include as Products under this Agreement by amendment, and
(b) any improvements, modifications or enhancements thereto
developed by ES to replace any prior version of a Product, as
provided in Section 2.6. The agreed form of an amendment to add
Products is set forth in Exhibit C.
1.4 “Specifications”
shall mean the technical and functional specifications pertaining
to the Products as listed in Exhibit B, as well as any changes or
additions to such Specifications as shall be made from time to
time.
1.5 “Media”
shall mean the cell culture media set forth in Exhibit
A.
1.6 “Confidential
Information” shall include, but is not limited to, (i) any
trade secrets relating to either party’s product plans,
development, designs, performance, protocols, costs, prices and
names, finances, marketing plans, business opportunities,
personnel, research development, formulae or know-how; and (ii) any
information designated by the disclosing party as confidential in
writing, or, if disclosed orally, reduced to writing and designated
as confidential within thirty (30) days; and (iii) the terms and
conditions of this Agreement, except (A) to the extent that a party
determines, in good faith, that disclosure of terms and conditions
of this Agreement is required under any applicable law, or (B) in
any proceeding to enforce this Agreement or to resolve any dispute
arising under this Agreement. “Confidential
Information” shall not include information
that: (i) is or becomes generally known or available by
publication, commercial use or otherwise through no fault of the
receiving party; (ii) is known and has been reduced to tangible
form by the receiving party at the time of the disclosure and is
not subject to restriction; (iii) is independently developed or
learned by the receiving party; (iv) is lawfully obtained from a
third party that has the right to make such disclosure; or (v) is
made generally available by the disclosing party without
restriction on disclosure.
1.7 “ES
Technology Rights” means the intellectual property rights
licensed to or owned by ES that relate to the manufacture, use,
sale, or import of Products, or derivatives or combinations
thereof, including but not limited to one or more of: i)
patents and patent applications, and all patents issuing from said
patents and patent applications, including any divisionals,
continuations and continuations-in-part (to the extent that they
cover the same subject matter of the original application), and
reissues and reexaminations of any such patents, together with all
non-US counterparts of the foregoing; and ii) copyrights (technical
publications), whether or not such copyrights are registered with
the US Library of Congress or other governmental body; (iii) use of
the ACTCellerate trademark and iv) any know-how, trade secret or
other proprietary information necessary to use or effectively
market and sell the Products.
1.8 “Net
Sales” means the invoiced amount on sales of Products and or
Media less (to the extent applicable and appropriately documented)
(i) sales, tariff and import duties, use and other taxes directly
imposed with reference to particular sales, (ii) permitted volume
discounts, rebates, and similar credits and chargebacks actually
allowed and taken (regardless of whether taken or paid at the time
of sale or paid or credited to the buyer at a subsequent date), and
(iii) amounts allowed or credited on returns; provided, any such
allowed deductions shall be listed on the invoice for the
applicable Product or otherwise documented in the ordinary course
of business..
2.1
Purchase and Supply of Products and Media
. During the term of this Agreement, ES agrees to supply
to and/or produce for Millipore any of the Products and Media as
Millipore shall require, upon the terms and conditions as stated
herein. Millipore and its Affiliates may at all times
sell the Products or Media using their own
labels. Millipore shall provide ES with non-binding
forecasts concerning the consignment of Products and Media and its
expected sales.
2.2
Co-Exclusive Distribution . The parties agree
that only Millipore and ES and any of their authorized Affiliates,
may sell the Products.
2.3
Specifications . The Specifications for the
Products and Media shall be used by Millipore as it unilaterally
deems appropriate on Millipore’s own Website and in its own
marketing and promotional materials. ES grants a non-exclusive,
non-royalty bearing right to Millipore and its Affiliates, during
the term of this Agreement to use the Specifications and/or images
obtained from ES’s datasheets as if it had full right title
and interest to the Specifications and/or any images contained
therein. ES shall obtain prior written approval from
Millipore of its acceptance of any modifications to the
Specifications prior to any Product or Media shipment.
2.4
Testing . ES shall be responsible for performing
verification testing (the “Quality Assurance Testing”)
and shall submit test reports to Millipore with each shipment of
Product and/or Media on a regular basis. ES shall
integrate this information into its systems (Control Plan, SOPs,
Checklists) for the sole purpose of testing, manufacturing and
supplying Products and Media to Millipore.
2.5
Finished Products; Document Retention . ES will
be responsible for delivery of finished Products, which meet the
Specifications, as may be amended from time to time, as well as any
other applicable governmental standards. ES will be
responsible for document generation and retention relative to all
pertinent parts of the process, including, but not limited to,
materials, manufacturing, inspection and testing, as generally
recommended for good manufacturing practice. ES shall
not ship any Products to Millipore which do not meet such
standards.
2.6
Improvements and Modifications of Products . If
ES develops an enhancement, improvement, or modification of any
Product or Media, ES shall inform Millipore, including a
description of the enhancement, improvement, or modification. The
improved and modified Products may replace or be sold in addition
to the existing Products under condition of mutual agreement
between ES and Millipore.
3.0
Terms of Consignment.
3.1
Pricing . The Products and Media shall be
consigned to Millipore as provided in Exhibit A and paid for upon
subsequent sale to Millipore’s
customers. .
3.2
Shipping . Unless instructed in writing by
Millipore, ES shall deliver the Products and Media, and related
documentation and information, DDP to Millipore’s designated
place of business (Incoterms 2000). All transportation
costs shall be borne by Millipore.
3.3
Purchase Orders; Order Procedures . Millipore
shall place all orders for Products and Media in a written purchase
order. Notwithstanding the foregoing, all transfer of
Products and Media to Millipore shall be subject to the provisions
of this Agreement and shall not be subject to the terms and
conditions contained in any purchase order of Millipore or
confirmation of ES, except insofar as any such purchase order or
confirmation establishes (i) the quantity of the Products and Media
to be transferred, or (ii) the shipment date or shipping
instructions of the Products and/or
Media. Millipore’s obligation to accept and pay
for the Products and Media shall be limited to products
specifically ordered by an authorized agent of Millipore, as
evidenced by a written purchase order. ES will use
commercially-reasonable best efforts to meet Millipore's requested
delivery schedules for Products and Media, but ES's obligation to
fulfill any purchase order is subject to availability of the
Products and Media. ES will maintain sufficient safety
stocks of the Products and Media to meet Millipore’s twelve
month non-binding purchase forecasts. ES reserves
the right to fulfill any order in part or through delivery in
installments. ES reserves the right to refuse, cancel or
delay shipment to Millipore if Millipore is delinquent in payments,
or when Millipore has failed to perform any of its obligations
under this Agreement.
3.4
Packaging . ES shall package each unit of
Products and Media to the Specifications and provide all Products
and Media in Millipore provided labels, unless instructed in
writing to the contrary by Millipore. ES shall deliver
the Products and Media, and related documentation and information
to Millipore or customer of Millipore in accordance with
Millipore’s specific routing instructions, including method
of carrier to be used. All transportation costs shall be
borne by Millipore and paid directly to the freight company;
provided, however, that if any transportation costs are not paid
directly by Millipore to the freight company, such costs shall be
invoiced to Millipore by ES and paid within forty-five (45) days of
the date shown on the invoice.
3.5
Inspection and Acceptance . All of the Products
and Media consigned to Millipore will be subject to
Millipore’s right of inspection and rejection of
non-conforming Products as provided in Section 3.6.
3.6
Nonconforming Products . If any of the Products
or Media delivered to Millipore fail to comply with the
Specifications, Millipore shall be entitled, in addition to its
other rights and remedies, to obtain replacement Products or
Media. Nonconforming products include any Product
purchased by Millipore with a Product expiration date earlier than
18 months after Millipore’s purchase in the case of Products
and 8 months in the case of Media; provided, that any expiration
date may be conditioned upon continuous storage of the Product at
temperatures and under conditions specified by ES. ES
shall replace such Products in a timely manner conditioned upon
return of defective or Nonconforming Products and shall reimburse
Millipore for the cost of the Nonconforming Products, including
transportation and handling costs, the cost of packaging materials
destroyed and the cost of removal, return and destruction of such
nonconforming Products or refund any money at Millipore’s
sole option.
3.7
Payment . Millipore shall pay ES a consignment
fee equal to [*Certain information has been omitted under a request
for confidential treatment, and the omitted information has been
filed with the Securities and Exchange Commission] of Net Sales of
Product other than Media. The consignment fee for Net
Sales of Media shall be $[*Certain information has been omitted
under a request for confidential treatment, and the omitted
information has been filed with the Securities and Exchange
Commission] for NC128, $[*Certain information has been omitted
under a request for confidential treatment, and the omitted
information has been filed with the Securities and Exchange
Commission] for M180, $[*Certain information has been omitted under
a request for confidential treatment, and the omitted information
has been filed with the Securities and Exchange Commission] for
NC124, and $[*Certain information has been omitted under a request
for confidential treatment, and the omitted information has been
filed with the Securities and Exchange Commission] for
N170. Should Millipore be required to pay royalties to
another party on Net Sales of Product or Media, the amount payable
to ES shall be reduced by the percentage owed to the other party,
provided however that the consignment fee rate shall be reduced no
less than fifty percent.
If Products
and/or Media are sold in combination with other biologically active
components or products that are not Products (a “Kit”),
Net Sales shall be calculated by mutual agreement.
All payments to
ES on account of Net Sales shall be made no later than forty-five
(45) days after the end of the calendar quarter in which the Net
Sales occurred. All payments shall be made in United
States dollars without deduction for taxes, assessments, exchanges,
collection or other charges of any kind. Conversion of
foreign currency to U.S. dollars shall be made at the conversion
rate reported in The Wall Street Journal on the last working day of
the calendar quarter to which the payment
relates. Payment shall be made by delivery of a check to
the principal office of ES or by wire transfer to an account
designated for such purpose by ES. If any payment is not
made in full when due and remains unpaid for more than five days
after the date due, late payments shall accrue interest at the rate
of one percent (1%) per month (twelve percent (12%) per annum) from
the date when such payment should have been made.
3.8 Net
Sales Reports . No later than forty-five (45)
days after the end of each calendar quarter, Millipore will deliver
to ES a statement which sets forth the quantity of each Product
and/or Media sold, Net Sales, and the amount of owed to ES on
account of Net Sales.
3.9
Records and Audit . Millipore shall keep and
maintain records of Net Sales and Product and Media inventory, with
respect to each and every Product and Media, during the term of
this Agreement. Such records shall be open to inspection
at Millipore’s principal office, at any reasonable time
within two (2) years after the period to which such records relate,
by an independent certified public accountant selected by ES and
retained at ES's expense; provided, however, that Millipore shall
bear the expense of an audit if the audit discloses that Millipore
has underpaid any amount of 10% or more during any three month
period or $10,000, whichever is greater. Said accountant
shall sign a confidentiality agreement (which shall not prohibit
disclosure of information in any lawsuit, arbitration or other
proceeding) and shall then have the right to examine the records
kept pursuant to this Agreement and report the findings of said
examination of records to ES as is necessary to (i) evidence that
records were or were not maintained and used in accordance with
this Agreement, and (ii) report any impropriety or inaccuracy in
the determination or payment of any amount due to be paid under
this Agreement. A copy of any report provided to ES by
the independent certified public accountant shall be given
concurrently to Millipore.
3.10
Sales Efforts . Millipore shall use its
commercially-reasonable best efforts to advertise, promote the sale
of, and sell the Products and Media.
4.
Scope of Agreement & Consideration for Co-Exclusive
Rights
4.1
License Rights . This Agreement sets forth the
terms and conditions that govern ES’s supply of Products and
Media to enable Millipore and its Affiliates to market, sell and
distribute such Products and Media under the ES Technology
Rights. ES hereby grants to Millipore and Millipore
hereby accepts a co-exclusive license under the ES Technology
Rights, without right to sublicense, for Millipore and its
Affiliates to import, offer for sale and sell Products and Media
worldwide. The foregoing grant of rights includes the right to (a)
convey to Millipore’s customers the ri